Member Info for Johnski

I note the job description states the requirement for-
"Desirable
Global mindset and experience working in an international business "
Who could doubt, with one thing after another, that this company is ready

"the good news is there's no bad news...the bad news is there's no good news"

I was doing some essential research into Syme today and see that AZ has added yet another addition to his repertoire, exciting new acquisition the Syme 55+ Centre in Toronto, is there no stopping this man. The good ladies organize clubs and classes including Pilates, Fit and Fun with Katrina and Cardio boost with Sylvia I suspect as an antedote to those long board room meetings. Thursday mornings we have Flex N Stretch and Fridays is Sit & Fit with Connie, multi tasking tensing and relaxing your bum whilst being interviewed for the Investor no doubt. There is a Syme Challenge, ‘We challenge you to walk with us or walk alone, get your body moving for Syme’. Great stuff.
They have handy hints for tired lth’s;- ‘Sleep routine’
Set a time to go to bed (no challenging the trolls after midnight, I’ve seen you, some of you are up at 3 or 4 in the morning, tsk tsk we all need our beauty winkies)
Unwind for the night by changing into your pooh bear jim jams and do your nightly routines, that is reciting 10 times ‘I must be nicer to trolls as they love cute kittens and puppies too’.
30 mins before bed avoid all technologies eg, TV, phones, laptops etc yes you know who you are,
Relax before bed by meditating, stretching or reading, (not looking at the current SP which has been the same since 4.30pm hoping in some magical way LSE have made a terrible error and it has been adjusted to £3.45p,
and finally,
Dim the lights, blow a kiss to the projected 6’ high image you have of AZ on the bedroom wall, and sleep.

Dr. Tom James is an Expert with 30+ years international experience. FinTech Entrepreneur. Fund Manager. Author. Musician. Space Enthusiast. Unlocking value in the Commodity & Energy Industry.

Tom is a serial FinTech entrepreneur with extensive industry expertise in the Commodity sector. He began programming computers at age 9 and after entering the Commodity Industry in 1989 launched his first International FinTech in 1999, SwapNet, it was the pioneer for Online Internet based Commodity Trading. More recently he co-founded the Trade Flow Funds in Singapore (2016) to address the massive US$1.5 Trillion dollar Trade Finance Gap faced by the Commodity Industry. After 2 years of FinTech development & Business planning the Digital Trade Finance Fund & Platform went live in 2018, operating the new approach to bulk physical Commodity trade & Inventory Finance. He is the business & system architect for the solution and holds the position of CEO and CIO. The solution which meets both industry needs and investor appetite combines a unique business model with proven risk management approaches, a fund platform, and Fintech for scalability. His co-founders complete the cross-discipline team necessary to develop and operate the trade finance solution & fund, coming from legal, maritime and I.T. backgrounds.

His 30 yrs+ commercial exposure has been gained through a broad range of senior executive roles in commodity trading, investment management, and commodity finance. His consultation is sought by Governments & Multinationals for advice in market developments and the health of business Ecosystems in the Energy & Commodity space. In 2014 he was called upon to serve as Senior Energy Advisor to the United States Department of Defense (TFBSO) and he currently sits on the Financing Advisory Resources panel for Enterprise Singapore. He co-founded the Technical Analysts Society of Singapore in 1999 & has been a Member of the Energy Institute (UK) since 1991. Tom is a successful published author, having documented and shared his extensive industry expertise through a series of 12 books and publications with Wiley Finance, Palgrave Macmillan, Springer and De Gruyter. Some of these textbooks have become required material for professional exams & university and have been cited by NASA, other Government agencies and Academics from around the world.

"do a runner" ??

Why do aardvarks make undesirable neighbors?
Because they always have their noses in other people's business!

To the people concerned. I have my shirt in this, 69 years old, I have put in everything I can afford, (and a small amount in Vela). If it didn't work i will have to look for a job stacking food shelves in Tesco's, BUT, I look at the business possibilities, I look at the people involved in making this happen, it is just nearly, so nearly, there for us all. Just keep the faith, keep strong in believing. i cannot see any way that this concept, this business, can do anything but be a success. Patience as we will hear news soon.

spot on Peak

Hi Ed from the world of operatic sentiment
“Based on both the inventory securitisation programme and the TradeFlow deal, we expect strong growth in revenues for Supply@ME in 2021” Great what’s not to like.
“We believe that there is potential for the shares to re-rate during the remainder of 2021 as the business plan progresses through its next stages”. Excellent, if only I had more money.
“The types of companies that can benefit from the Supply@ME offering can be found across a wide range of industry groups, including wholesalers, food production and general industrials”. Just about everything then.
“it is a tool to be used as a structural element of company balance sheet management”. great, just been down the back of my sofa again.. 3p so that’s another 9 shares
“The market opportunity for Supply@ME is vast…” Oh Ed, that is so sexy, er man to man stuff of course
“acquisition of TradeFlow” yes, so amped, which means “enlarged footprint in terms of both funding background, sources and customer origination” amped again man
“we believe that Supply@ME will realise a substantial uplift in revenues during the remainder of 2021” triple amped
“attract additional corporate clients” quiggly
“rapid transition to positive profitability” juiced man
“A unique and rapidly scalable product and, accordingly, technology platform” yahoo
“model based on fee income rather than on use of Supply@ME’s own balance sheet” shiney giney
“a general retailer could have 1/6 (62/365) of a year’s worth of sales tied up in inventory”. Horangi! How many general retailers are there?
“provides is a monetisation solution for the inventory end of the working capital cycle, allowing businesses to reduce their "days inventory held" metric, and therefore to free up balance sheet resources to be deployed elsewhere in their business” hot in the biscuit, spewin’ rainbows!
“approved by the Shariah scholar board. This platform greatly expands Supply@Me’s reach within the Middle East-North Africa (MENA) region”. Hot diggity dank I’m having kittens
“the acquisition of a bank as a captive source of funding”. I’m happier than a opossum in a turned over trash can.
“Following this update to the captive bank strategy, Supply@ME has entered into a term sheet with an Italian banking group to acquire 10% of the capital of a fintech licensed bank, with the option to acquire an additional 10% within the following two years”. oltre la gioia eccitata
“establishment of a legally backed digital version of physical inventory” polysaturation man
“inventory monetisations will drive the rapid transition to profitability in our forecasts” flambunctious!
“We believe that Supply@ME is on track to begin recognising significant revenues during FY 2021” wowzers
ok so now the bad news? The Tool always says at the end they would not invest so, lets have it?
“Based on our assumptions, Supply@ME will become profitable by the end of FY Dec 2021, with profit growing robustly thereafter”. gulp

"When you get into a tight place and everything goes against you, till it seems as though you could not hang on a minute longer, never give up then, for that is just the place and time that the tide will turn".

Harriet Beecher Stowe

The proactive investors is such a good read, you would think the SP would be higher. 'Our greatest songs are still unsung' and will soon be here!

Angus 'Yes I am happy to hold but still ****ting my pants'.... makes perfect sense to me. "May the bridges i burn light my way". i don't know who said it but this is either courage under fire or folly Angus, but I think lth's are showing their metal in staying with this just a little bit longer. It will come good. I have stopped looking at my HL balance, just concentrating on the future.
“Patience is not sitting and waiting, it is foreseeing. It is looking at the thorn and seeing the rose, looking at the night and seeing the day. Lovers are patient and know that the moon needs time to become full.” Rumi

i dont get it...last week was say .0003 of a difference, x 72000000 = £21600 lost profit. I suppose that is peanuts to these people dealing in millions. I realise now what small fry I am! hope my maths is right there too!

although there must be a buyer, why would you sell 72000000 shares when the price is at its lowest? or is it a buy and just the quirk of algorithm? the sale at 10.46 looks like a sale in a sea of buys..

£85200 on 24000000 shares...wow, somebody is seriously wealthy, seriously keen on syme, and I'm seriously jealous. They, or the institution for these two buys, must know something. Come on England, come on Syme.

A wife says to her husband: "Choose, it's either me or football." The husband responds: "Give me 90 minutes to think about it."

For those who may not have looked at his CV...
Professor Sir Christopher Evans, OBE
DSc, PhD, BSc, ARCS, F.Med.Sci, FR Eng, FRSC, FRSA, FIBiol, FIOM, CCMI, C.Biol., CSci, C.Chem
Twice elected "Cambridge Businessman of the Year", awarded OBE in 1995, knighted in 2001. Has created over 50 successful science companies from scratch worth over $5billion. He has successfully floated 20 new companies on stock markets around the world.

His businesses have employed over 3500 people, mostly scientists, spending over $300million each year with life sciences suppliers and with an annual salary base in excess of $200million. He built Chiroscience plc with many of his own scientific ideas from scratch with £1.5million in 1992 to over £1billion by 1997 returning huge amounts of cash at over 240% IRR to his original backers (Apax, Schroders, 3i etc). He built Merlin Biosciences in just six years to over $500million investment funds under management into one of the largest European focused biomedical venture capital firms ever: it is now renamed Excalibur.

His companies have developed and launched a diversity of interesting new products and treatments;- world’s first premature infant lung surfactant; one of the safest anaesthetic epidurals; an ultra pure anti-inflammatory; a range of leading dermatology instruments; diabetic leg ulcer device; a range of cancer and HIV diagnostic tests and bioluminescent germ testing kits etc

This COVID-related research project, was arranged and structured by him, through Excalibur Medicines Ltd, which brought together the scientific intellectual property, international funding and a world leading team to drive the project forward. The idea of investigating AZD1656 in this setting was conceived by Professor John Martin and his team at St George Street.
Professor Evans and the Excalibur team having sourced investment from Mubadala of Abu Dhabi, one of the world’s leading sovereign wealth funds, Excalibur itself and several high net worth individuals. This is in addition to funding secured from the UK Government through the UKRI / Innovate UK programme.
Professor John Martin, Chairman of the charity and Principal Investigator on the grant awarded by UKRI, said: “Novel research thinking in an interdisciplinary group combined with the drive of the charity and the excellent relationship we have with Astra Zeneca have produced the potential for a great therapeutic leap. This also has potential for non-diabetic patients with COVD-19.”
He also has a dog called Norris.

When Professor Evans states “This drug has the potential to make a real difference to people with diabetes who contract coronavirus. The completion of the trial is a very significant moment, we look forward to seeing the results from the data collected. The trial completion enables us to progress commercialisation plans.”
The idea that a man like this is unaware of exactly what progress has been made, is inconceivable, imo.

Professor Evans said: “This drug has the potential to make a real difference to people with diabetes who contract coronavirus. The completion of the trial is a very significant moment, we look forward to seeing the results from the data collected. The trial completion enables us to progress commercialisation plans.”
I cannot envisage Professor Evans saying in a few weeks time that he is having to unpick the progress on commercialisation plans because their has not been significant distinct results, after all, he did't have to say the trial completion enables us to progress commercialisation plans. Are we really to assume he has not spoken to anyone involved in this trial ever and formed an impression of the result? maybe he hasn't, but my kid's inheritance is on that he has. GLA, DYOR, all in my opinion of course and I have bombed out of AIM shares before!

“SGS and Excalibur Medicines Ltd ("EML") have begun the process of progressing commercialisation plans, subject to the trial data being successful”, they wouldn’t be doing this knowing that the trial was not at least hinting at a positive imo.

“Analysis is based broadly on a combination of the anticipated mechanism of the drug and the relevant data from the trial endpoints - reduction in mortality, slowing in disease progression, glycaemic and inflammatory reduction, the possible up-regulation of T-reg cell activity promoting long term immunity beyond the normal life of a vaccine”.
Previous trials have shown;-

AZD1656 (AZD1656 (GCK activator, 1 µM) has been shown to activate the migration of T regulatory cells to sites of inflammation in preclinical experiments. This migration of Treg cells to inflamed tissue is crucial for their immune-modulatory function (Kishore et al (2017) GCK activation significantly enhanced Treg cell migration to the inflamed tissue. Tregs not only maintain the tone and tenor of an immune response by dominant tolerance but have also been identified as key players in resolving tissue inflammation and as mediators of tissue healing.
Research docs link;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714502/

AZD 1656 has been found to be safe in almost 1,000 patients with diabetes and has a blood glucose lowering effect for four months ie IMO sufficient to cover the critical period likely in hospital with covid 19. Blood glucose control has been proposed as a key factor in reducing complications from COVID-19 in diabetics. Research docs link;
https://europepmc.org/article/med/22943931

In the safety and tolerability of AZD1656 in the management of diabetes in hospitalised diabetic patients with known or suspected COVID-19, AZD1656 has been studied in single doses of up to 180 mg and multiple doses to 150 mg BID for 8 days in healthy volunteers as well as alone and in combination with other blood glucose control agents in diabetic patients at 200 mg daily for up to 6 months duration. In both healthy volunteers and diabetic patients no significant clinical effects other than glucose lowering were noted. Research docs link;
https://openinnovation.astrazeneca.com/azd1656.html

To determine whether AZD1656 affects duration of hospital stay, requirement for mechanical ventilation or mortality in diabetic patients with known or suspected COVID-19.
To be determined in trial.

Link to multiple (24) trials by AstraZenaca on AZD1656;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/SearchResults

Gemini is described as the "light of inter-play," spirit and form. Gemini’s are curious, talkative, versatile and mentally active. The Twins go everywhere together, hand-in-hand, symbolizing dual nature, good and evil, male and female, in and out, yin and yang, playful and intellectually curious. They are the social butterflies of the zodiac, these quick-witted twins can talk to anyone about anything. Find them buzzing between happy hours, dinner parties, and dance floors and bulletin boards.
Brass has commented here 40 times in the last month. Why? when he is not invested? Why the interest? There must be an angle? Bright guy like him, wanting to trade, to make money, but hanging around low life on a penny share, not even worth half a penny, insulting genuine people, genuine investors. Very strange. Beware.
Is Brass first class or just natural gas.

I wrote to Vela last week asking when we might hear the results of the trials specifically.
The reply I received was from Brent Fitzpatrick, (MBE Non-executive Chairman)'s email address saying 'we hope to update the market shortly'. I would imagine he is far too busy to answer emails from the likes of me however it must have been his office so I take 'we hope shortly' to mean this week or next.